Clearside Biomedical (CLSD) announced that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmology, AAO, and preceding events that highlighted encouraging safety and efficacy data from clinical trials of therapies utilizing Clearside’s SCS Microinjector(R) to deliver drugs into the suprachoroidal space to treat a variety of retinal diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLSD:
- Largest borrow rate increases among liquid names
- Clearside Biomedical management to meet with JMP Securities
- Biotech Alert: Searches spiking for these stocks today
- Stifel bullish on Clearside Biomedical as CLS-AX meets goals in Phase 2b ODYSSEY
- Morning Movers: Arcadium Lithium surges after deal to be acquired
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
